Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials (Q80698928)
Jump to navigation
Jump to search
scientific article published on 01 August 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials |
scientific article published on 01 August 2007 |
Statements
Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials (English)
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference